Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
National Cancer Institute (NCI)
Incyte Corporation
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
University of Manitoba
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Karyopharm Therapeutics Inc
University of Turin, Italy
Stanford University
Ohio State University Comprehensive Cancer Center
Incyte Corporation
Incyte Corporation
Hackensack Meridian Health
Dana-Farber Cancer Institute
Incyte Corporation
M.D. Anderson Cancer Center
Prelude Therapeutics
City of Hope Medical Center
Incyte Corporation
Takeda
Center for International Blood and Marrow Transplant Research
University of Washington
Incyte Corporation
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, Irvine
City of Hope Medical Center
Disc Medicine, Inc
Massachusetts General Hospital
Novartis
University Hospital, Angers
Azienda Ospedaliero-Universitaria di Parma
Azienda Ospedaliero-Universitaria di Parma
M.D. Anderson Cancer Center
Mayo Clinic
University of Miami
Dartmouth-Hitchcock Medical Center
Azienda Ospedaliero-Universitaria di Parma
Memorial Sloan Kettering Cancer Center